
IRIDEX Corporation IRIX
$ 1.03
3.35%
Annual report 2026
added 04-02-2026
IRIDEX Corporation Cost of Revenue 2011-2026 | IRIX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue IRIDEX Corporation
| 2026 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 33.4 M | 29.2 M | 30.1 M | 31.6 M | 20.8 M | - | 25.5 M | 25.1 M | 26.1 M | 25.3 M | 21.4 M | - | 19.7 M | 17.5 M | 16.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 33.4 M | 16.9 M | 24.8 M |
Quarterly Cost of Revenue IRIDEX Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.47 M | 8.89 M | 6.84 M | - | 7.26 M | 7.5 M | 7.3 M | - | 7.23 M | 7.49 M | 7.77 M | - | 8.18 M | 7.49 M | 7.41 M | - | 7.48 M | 7.32 M | 7.02 M | - | 5.15 M | 3.81 M | 5.1 M | - | 6.38 M | 5.88 M | 6.34 M | - | 6.74 M | 6.04 M | 5.59 M | 8.07 M | 6.49 M | 5.51 M | 6.02 M | 6.97 M | 5.54 M | 6.17 M | 6.63 M | - | 4.97 M | 4.82 M | 5.39 M | - | 4.97 M | 5.29 M | 5.27 M | - | 4.8 M | 4.73 M | 4.71 M | - | 3.97 M | 4.33 M | 4.32 M | - | 4.27 M | 4.15 M | 4.11 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.89 M | 3.81 M | 6.09 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Globus Medical
GMED
|
958 M | $ 90.0 | 1.58 % | $ 12.2 B | ||
|
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | ||
|
AdaptHealth Corp.
AHCO
|
2.64 B | $ 11.94 | -1.08 % | $ 1.61 B | ||
|
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | ||
|
Helius Medical Technologies
HSDT
|
583 K | $ 1.83 | -3.68 % | $ 1.11 M | ||
|
Integra LifeSciences Holdings Corporation
IART
|
728 M | $ 9.33 | 0.21 % | $ 719 M | ||
|
ClearPoint Neuro
CLPT
|
14.3 M | $ 9.07 | -3.3 % | $ 257 M | ||
|
Bruker Corporation
BRKR
|
1.72 B | $ 36.67 | -0.19 % | $ 5.46 K | ||
|
Integer Holdings Corporation
ITGR
|
1.35 B | $ 85.11 | -0.61 % | $ 2.96 B | ||
|
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 15.76 | -1.13 % | $ 370 M | ||
|
LENSAR
LNSR
|
31.3 M | $ 5.63 | -4.41 % | $ 67.3 M | ||
|
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | ||
|
Medtronic PLC
MDT
|
11.6 B | $ 86.42 | 0.15 % | $ 111 B | ||
|
Myomo
MYO
|
14 M | $ 0.68 | -3.62 % | $ 28.5 M | ||
|
EDAP TMS S.A.
EDAP
|
36 M | $ 3.4 | -1.73 % | $ 127 M | ||
|
Orthofix Medical
OFIX
|
256 M | $ 11.71 | -0.51 % | $ 464 M | ||
|
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | ||
|
Align Technology
ALGN
|
1.2 B | $ 166.87 | -2.91 % | $ 12.5 B | ||
|
AxoGen
AXGN
|
57.9 M | $ 30.99 | -5.06 % | $ 1.43 B | ||
|
Insulet Corporation
PODD
|
768 M | $ 202.46 | -0.51 % | $ 14.2 B | ||
|
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | ||
|
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | ||
|
Neovasc
NVCN
|
556 K | - | - | $ 111 M | ||
|
Sintx Technologies
SINT
|
557 K | $ 2.66 | 5.14 % | $ 7.38 M | ||
|
Smith & Nephew plc
SNN
|
1.54 B | $ 31.73 | -2.74 % | $ 23.8 B | ||
|
Stryker Corporation
SYK
|
9.05 B | $ 332.07 | -0.1 % | $ 127 B | ||
|
Tactile Systems Technology
TCMD
|
79.4 M | $ 24.05 | -2.12 % | $ 550 M | ||
|
Butterfly Network
BFLY
|
33.2 M | $ 4.05 | -1.94 % | $ 857 M | ||
|
Tandem Diabetes Care
TNDM
|
469 M | $ 18.28 | -4.64 % | $ 1.24 B | ||
|
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.61 | 3.37 % | $ 38 M | ||
|
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | ||
|
Delcath Systems
DCTH
|
11.8 M | $ 9.67 | -0.31 % | $ 346 M | ||
|
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
6.22 B | $ 61.86 | -1.17 % | $ 91.6 B | ||
|
Alphatec Holdings
ATEC
|
232 M | $ 11.03 | 0.55 % | $ 1.66 B | ||
|
Varex Imaging Corporation
VREX
|
554 M | $ 10.59 | 0.28 % | $ 438 M | ||
|
CONMED Corporation
CNMD
|
624 M | $ 34.54 | 1.35 % | $ 1.07 B | ||
|
Beyond Air
XAIR
|
5.37 M | $ 0.71 | 0.14 % | $ 48.1 M |